Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | STK33 | Q9BYT3 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7815425 | 0.90 | KDR (0.45) | GSK3BKDRPDE4BPDE4DCAMK2D | |
| Acetic Acid SCHEMBL7815404 | 0.89 | MMP13 (0.41) | ALDH1A1MEN1CYP1A2MAPTCYP2C19 | |
| Acetic Acid SCHEMBL7821076 | 0.89 | CAMK2D (0.38) | ALDH1A1MEN1CYP1A2MAPTCYP2C19 | |
| Acetic Acid SCHEMBL7815149 | 0.88 | TDP1 (0.42) | ALDH1A1MEN1CYP1A2MAPTCYP2C19 | |
| Acetic Acid SCHEMBL7821231 | 0.87 | CAMK2D (0.41) | ALDH1A1MEN1MAPTKMT2ASTK33 | |
| Acetic Acid SCHEMBL7806966 | 0.87 | PDE4B (0.41) | ALDH1A1MEN1CYP1A2MAPTCYP2C19 | |
| Acetic Acid SCHEMBL7807598 | 0.86 | GRIN2D (0.38) | STK33KDRCAMK2DEGLN1 | |
| Acetic Acid SCHEMBL7821471 | 0.85 | PDE4B (0.37) | ALDH1A1GSK3BQPCTKDRPDE4B | |
| Acetic Acid SCHEMBL7817838 | 0.85 | FLT3 (0.41) | ALDH1A1MEN1CYP1A2MAPTCYP2C19 | |
| Acetic Acid SCHEMBL7814729 | 0.84 | MMP13 (0.42) | ALDH1A1GSK3BQPCTFLT3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010025043-A1 | New pharmaceutical active compounds | ASTRA AKTIEBOLAG, A SWEDEN CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6271231-B1 | Pharmaceutically active compounds | ASTRA AKTIEBOLAG (SE) | 2001-08-07 | — | — | US | disclosed |
| EP-0929551-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | Astra Aktiebolag (publ) (SE) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013368-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRA AKTIEBOLAG (PUBL) (SE) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025043-A1 | New pharmaceutical active compounds | CSNK1A1, CSNK1G1, CSNK2A1 | ALDH1A1 2487/4885MEN1 964/4885CYP1A2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.